Alphamab Oncology
HKEX:9966
Alphamab Oncology
Operating Income
Alphamab Oncology
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alphamab Oncology
HKEX:9966
|
Operating Income
-¥198.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Operating Income
-¥12B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Operating Income
-¥1.1B
|
CAGR 3-Years
-36%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Operating Income
¥1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Operating Income
¥9.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
46%
|
CAGR 10-Years
47%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Operating Income
¥1.4B
|
CAGR 3-Years
59%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
See Also
What is Alphamab Oncology's Operating Income?
Operating Income
-198.4m
CNY
Based on the financial report for Dec 31, 2023, Alphamab Oncology's Operating Income amounts to -198.4m CNY.
What is Alphamab Oncology's Operating Income growth rate?
Operating Income CAGR 5Y
-1%
Over the last year, the Operating Income growth was 51%. The average annual Operating Income growth rates for Alphamab Oncology have been 18% over the past three years , -1% over the past five years .